Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?
作者信息
Chan Noel, Eikelboom John
机构信息
Population Health Research Institute, Hamilton, Ontario, Canada and Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada.
出版信息
Eur Heart J. 2021 Aug 31;42(33):3143-3145. doi: 10.1093/eurheartj/ehab417.
Abstract
摘要
相似文献
1
Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?新冠病毒感染中的高凝状态与血栓形成：一个可改变的死亡原因？
Eur Heart J. 2021 Aug 31;42(33):3143-3145. doi: 10.1093/eurheartj/ehab417.
2
Covid-19, hypercoagulability and risk of mortality in schizophrenia.新冠病毒、高凝状态与精神分裂症患者的死亡率风险。
Actas Esp Psiquiatr. 2021 Jul;49(4):194-195. Epub 2021 Jul 1.
3
Intra-arterial thrombosis associated with COVID-19.与新型冠状病毒肺炎相关的动脉内血栓形成
J Vasc Surg. 2020 Aug;72(2):757-758. doi: 10.1016/j.jvs.2020.05.019. Epub 2020 May 17.
4
Thromboelastographic Results and Hypercoagulability Syndrome in Patients With Coronavirus Disease 2019 Who Are Critically Ill.新冠肺炎危重症患者血栓弹力图结果与高凝综合征。
JAMA Netw Open. 2020 Jun 1;3(6):e2011192. doi: 10.1001/jamanetworkopen.2020.11192.
5
Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients.采用旋转血栓弹力图评估新型冠状病毒肺炎患者的高凝状态。
Thromb Res. 2020 Dec;196:379-381. doi: 10.1016/j.thromres.2020.08.046. Epub 2020 Sep 1.
6
Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II.2019冠状病毒病（COVID-19）中的止血维持与血栓形成预防：第二部分。
Semin Thromb Hemost. 2021 Jun;47(4):333-337. doi: 10.1055/s-0041-1728775. Epub 2021 Jun 1.
7
Hyper- and hypocoagulability in COVID-19 as assessed by thromboelastometry -two case reports.COVID-19 中通过血栓弹力描记术评估的高凝和低凝状态——两例病例报告。
Korean J Anesthesiol. 2021 Aug;74(4):350-354. doi: 10.4097/kja.20327. Epub 2020 Aug 10.
8
Multiple Thrombotic Events in a 67-Year-Old Man 2 Weeks After Testing Positive for SARS-CoV-2: A Case Report.一名67岁男性在SARS-CoV-2检测呈阳性两周后发生多次血栓形成事件：病例报告
Am J Case Rep. 2020 Jul 22;21:e925786. doi: 10.12659/AJCR.925786.
9
COVID-19 versus HIT hypercoagulability.COVID-19 与 HIT 高凝状态。
Thromb Res. 2020 Dec;196:38-51. doi: 10.1016/j.thromres.2020.08.017. Epub 2020 Aug 10.
10
Reply to "High frequency of Antiphospholipid Antibodies in Critically ill COVID-19 patients: a Link with Hypercoagulability?".对《危重症 COVID-19 患者中抗磷脂抗体的高频率：与高凝状态有关联？》的回复
J Intern Med. 2021 Mar;289(3):425-426. doi: 10.1111/joim.13159. Epub 2020 Sep 9.
引用本文的文献
1
Research progress of NF-κB signaling pathway and thrombosis.NF-κB 信号通路与血栓的研究进展。
Front Immunol. 2023 Sep 29;14:1257988. doi: 10.3389/fimmu.2023.1257988. eCollection 2023.
2
The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants.新冠病毒病的最佳抗凝策略：预防性还是治疗性？：对超过27000名参与者的荟萃分析、试验序贯分析和荟萃回归分析
Emerg Crit Care Med. 2022 Sep;2(3):148-166. doi: 10.1097/EC9.0000000000000059. Epub 2022 Sep 16.
3
Doxycycline's Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study.多西环素在降低 COVID-19 危重症患者血栓形成和死亡率中的潜在作用：一项多中心队列研究。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231177017. doi: 10.1177/10760296231177017.
4
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.COVID-19 的免疫疗法：IL-6 信号通路内外
Front Immunol. 2022 Feb 22;13:795315. doi: 10.3389/fimmu.2022.795315. eCollection 2022.
5
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges.抗冠状病毒疗法（ACT）试验：设计、基线特征及挑战
CJC Open. 2022 Jun;4(6):568-576. doi: 10.1016/j.cjco.2022.02.010. Epub 2022 Mar 1.
Zotero 插件